In June 2013 the World Health Organization released new guidelines for HIV paediatric care, increasing the number of children recommended for treatment and updating the preferred treatment regimens for different age groups based on the latest clinical evidence. Closing the treatment gap for children will require efforts on many levels. This includes the development of appropriate and affordable formulations, specifically as fixed-dose combinations (FDCs), which are needed to implement the treatment guidelines and simplify treatment in a way that contributes to treating more HIV positive children. The Satellite will provide a follow up to a similar satellite organized at the IAS Conference in Kuala Lumpur in 2013 and will look at where we stand one year later in closing the treatment gap for children living with HIV. This Satellite will include the presentation of the Paediatric HIV Treatment Initiative recently launched by the Medicines Patent Pool, UNITAID and the Drugs for Neglected Diseases Initiative.

Agenda

Overview of the paediatric market
Carmen Perez Casas, UNITAID

The 2013 treatment guidelines and key implementation challenges
Martina Penazzato, World Health Organization

Forecasting needs and strategizing adoption of new formulations for children
Nandita Sugandhi, Clinton Health Access Initiative

Missing formulations for paediatric HIV treatment and the Dakar Call for Action
Marc Lallemant and Janice Lee, Drugs for Neglected Diseases Initiative

The Paediatric HIV Treatment Initiative to speed up the development of the missing formulations
Sandeep Juneja, Medicines Patent Pool

Panel of stakeholder perspectives on addressing the challenges with respect to paediatric formulations for HIV treatment
Luann Hatane, Pediatric AIDS Treatment for Africa
Assumpta Reginald, ICW, Nigeria
Polly Clayden, HIV i-base, UK
Linda Lewis, US Food and Drug Administration
Helen McDowell, Viiv Healthcare, UK
Jaideep Gogtay, Cipla, India

Reception to follow